Focal therapy today: upsides and downsides

While there is considerable allure to the theory behind focal therapy (and focal laser therapy or FLA in particular) as a treatment for some men with localized prostate cancer, it is worth understanding that there are good reasons to consider this allure with great caution. … READ MORE …

The Prostate Health Cocktail in management of biochemically recurrent prostate cancer

A newly published paper by some highly regarded researchers provides data from a small, Phase II trial of Prostate Health Cocktail (PHC) — an “over-the-counter” combination herbal supplement — in the management of biochemical recurrence of prostate cancer. … READ MORE …

HHV8 infection NOT associated with risk for prostate cancer

Over the years there have been many suggestions that prostate cancer may be “caused” by one or more viral or bacterial infections. … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

Access to, cost of, and value of high-price prostate (and other) cancer drugs

As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …

Risk for conversion from minimally invasive to open surgery for prostate cancer patients

A new paper in the Journal of Urology provides us with a detailed assessment of the likelihood of and the risks associated with the need to convert from a minimally invasive (e.g., robot-assisted) to an open surgical procedure during the course of a radical prostatectomy. … READ MORE …

New US national prostate cancer data classified by NCCN risk category

Prior to 2013, when the National Cancer Institute released accumulated, de-identified, prostate cancer-specific patient data from the national SEER cancer registry, those data only included the post-surgical, pathological Gleason scores and not the biopsy Gleason scores. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,169 other followers